Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin

Summary

Plasmas from 16 patients that were found to be positive both for anticardiolipin antibodies (ACA) and lupus anticoagulants (LA) were incubated with liposomes that contained anionic phospholipids. In 11 of these plasmas, ACA could be cosedimented with the liposomes in a dose-dependent manner, whereas LA activity of the remaining supernatant was unaffected. LA activity of purified total IgG from 6 patients was measured in three different coagulation tests, using normal plasmas from different species. Prolongation of the aPTT, KCT and dRW clotting times was observed only with normal plasma from human origin, not with bovine, rat or sheep plasma.

Highly purified coagulation factors Xa, Va and prothrombin, both of human and bovine origin, were used to establish for two patient IgG's the effect of LA on the rate of thrombin formation in the presence and absence of lipid vesicles composed of 20 mole% phosphatidylserine and 80 mole% phosphatidylcholine. A strong and dose dependent inhibition by LA was observed only when human prothrombin was used as substrate in the prothrombinase complex in the presence of lipids. No inhibition was found when bovine prothrombin was used as substrate. The inhibitory effect observed in the presence of human prothrombin was independent of the source of factors Xa and Va, and was not found in the absence of lipid. Preliminary binding studies suggest that LA only associate with a lipid surface, provided that human prothrombin and calcium ions are present. These data indicate that LA are not directed to phospholipids alone, but presumably recognize an epitope which becomes exposed upon Ca²⁺-mediated binding of human prothrombin to phospholipids.

• References

• 1 Harris NE, Balestrieri G, Tincani A, Gharavi AE. The immunology of phospholipid-binding antibodies in the antiphospholipid syndrome and related disorders. In: Phospholipid-binding Antibodies.. Harris EN, Exner T, Hughes GRV, Asherson RA. (eds) CRC Press, Inc.: 1991. pp 123-37
• 2 Loizou S, McCrea JD, Rudge AC. et al. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-44
• 3 Exner T, Triplett D. Lupus anticoagulants: characteristics, methods of laboratory detection and some clinical associations. In: Phospholipidbinding Antibodies.. Harris EN, Exner T, Hughes GRV, Asherson RA. (eds) CRC Press, Inc.: 1991. pp 141-58
• 4 Pengo V, Hein MJ, Thiagarajan P, Shapiro SS. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69-76
• 5 Harris EN, Gharavi AE, Tincani A. et al. Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol 1985; 17: 155-62
• 6 Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun 1988; 155: 1001-7
• 7 McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73: 506-13
• 8 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4
• 9 Galli M, Comfurius P, Maassen C. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7
• 10 Schousboe I. β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91
• 11 Nimpf J, Bevers EM, Bomans PHH. et al Biochim Biophys Acta. 1986; 844: 142-9
• 12 Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-6
• 13 Exner T, Rickard KA, Kronenberg H. Sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-51
• 14 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell's viper venom time for the diagnosis of lupus anticoagulant. Blood 1986; 68: 869-75
• 15 Rosing J, Tans G, Govers-Riemslag JW. et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83
• 16 Tans G, Rosing J, Thomassen MCLGD, Heeb MJ, Zwaal RFA, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-8
• 17 Bevers EM, Comfurius P, van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36
• 18 Clyne LP. Species specificity of lupus-like anticoagulants. Blut 1986; 53: 287-92
• 19 Loeliger A. Prothrombin as co-factor in the circulating anticoagulant in systemic lupus erythematosus?. Thromb Diath Haemorrh 1959; 3: 237-56
• 20 Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immuno-electrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-13
• 21 Fleck RA, Rapaport SI, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9
• 22 Rivard GE, Schiffman S, Rapaport SI. Cofactor of the "Lupus Anticoagulant". Tromb Diath Haemorrh 1974; 32: 554-63
• 23 Hamilton HK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for the assembly of the prothrombinase complex. J Biol Chem 1990; 265: 3809-14
• 24 Comfurius P, Senden JMG, Tilly RHJ, Schroit AJ, Bevers EM, Zwaal RFA. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibiton of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026: 153-160